Krystal Biotech Q3 2020 Earnings Report
Key Takeaways
Krystal Biotech reported its Q3 2020 results, highlighting the initiation of pivotal trials for DEB, ARCI and aesthetic skin conditions. The company also announced positive preclinical data for KB407 in cystic fibrosis and reported a strong balance sheet with $286.4 million in cash, cash equivalents and short-term investments.
Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021.
Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars was initiated.
Additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis was announced.
Cash, cash equivalents and short-term investments of $286.4 million as of September 30, 2020.
Krystal Biotech
Krystal Biotech
Forward Guidance
Krystal Biotech anticipates top line data and BLA filing in 2021, in line with prior guidance. Data from this trial will also form the basis of an MAA filing in the EU which is anticipated to occur shortly after the BLA filing.